Info

Exelixis, Inc. is a biotechnology company engaged in the development of differentiated pharmaceutical products for the treatment of cancer and other serious diseases. Exelixis has a pipeline of compounds in various stages of development that will potentially treat cancer, renal disease and various metabolic and cardiovascular disorders. The Company has 11 compounds in clinical development: XL647, XL880, XL820, XL184, XL518, XL281, XL019, XL844, XL228, XL147 and XL765. The Company has ongoing commercial collaborations with several pharmaceutical and biotechnology companies, including SmithKline Beecham Corporation (which does business as GlaxoSmithKline), Bristol-Myers Squibb.(Source: 10-K)